Heart failure drug treatment

The Lancet

Volumn 393, Issue 10175, 2019, Pages 1034-1044

  Rossignol, Patrick ^a   Hernandez, Adrian F ^b   Solomon, Scott D ^c   Zannad, Faiez ^a  

^a UNIVERSITÉ DE LORRAINE   (France)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 1 RECEPTOR ANTAGONIST; DIURETIC AGENT;

ACUTE DISEASE; CLASSIFICATION; DISEASE EXACERBATION; DRUG EFFECT; HEART FAILURE; HEART STROKE VOLUME; HUMAN; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ACUTE DISEASE; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; DISEASE PROGRESSION; DIURETICS; HEART FAILURE; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SODIUM-GLUCOSE TRANSPORTER 2 INHIBITORS; STROKE VOLUME;

EID: 85062374412     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(18)31808-7     Document Type: Review

References (104)

1. Braunwald, E, Heart failure. JACC Heart Fail 1 (2013), 1–20.
2. Zannad, F, Rising incidence of heart failure demands action. Lancet 391 (2018), 518–519.
3. Hunt, SA, Abraham, WT, Chin, MH, et al. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing committee to update the 2001 guidelines for the evaluation and management of heart failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation 112 (2005), e154–e235.
4. Ponikowski, P, Voors, AA, Anker, SD, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 37 (2016), 2129–2200.
5. Yancy, CW, Jessup, M, Bozkurt, B, et al. 2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 128 (2013), 1810–1852.
6. Girerd, N, Seronde, MF, Coiro, S, et al. Integrative assessment of congestion in heart failure throughout the patient journey. JACC Heart Fail 6 (2018), 273–285.
7. Ziaeian, B, Fonarow, GC, The prevention of hospital readmissions in heart failure. Prog Cardiovasc Dis 58 (2016), 379–385.
8. Senni, M, Gavazzi, A, Oliva, F, et al. In-hospital and 1-year outcomes of acute heart failure patients according to presentation (de novo vs worsening) and ejection fraction. Results from IN-HF Outcome Registry. Int J Cardiol 173 (2014), 163–169.
9. Bergethon, KE, Ju, C, DeVore, AD, et al. Trends in 30-day readmission rates for patients hospitalized with heart failure: findings from the get with the guidelines-heart failure registry. Circ Heart Fail, 9, 2016, e002594.
10. Maggioni, AP, Dahlstrom, U, Filippatos, G, et al. EURObservational Research Programme: regional differences and 1-year follow-up results of the Heart Failure Pilot Survey (ESC-HF Pilot). Eur J Heart Fail 15 (2013), 808–817.
11. Tromp, J, Tay, WT, Ouwerkerk, W, et al. Multimorbidity in patients with heart failure from 11 Asian regions: a prospective cohort study using the ASIAN-HF registry. PLoS Med, 15, 2018, e1002541.
12. Damasceno, A, Mayosi, BM, Sani, M, et al. The causes, treatment, and outcome of acute heart failure in 1006 Africans from 9 countries. Arch Intern Med 172 (2012), 1386–1394.
13. Dokainish, H, Teo, K, Zhu, J, et al. Global mortality variations in patients with heart failure: results from the International Congestive Heart Failure (INTER-CHF) prospective cohort study. Lancet Glob Health 5 (2017), e665–e672.
14. Crespo-Leiro, MG, Anker, SD, Maggioni, AP, et al. European Society of Cardiology Heart Failure Long-Term Registry (ESC-HF-LT): 1-year follow-up outcomes and differences across regions. Eur J Heart Fail 18 (2016), 613–625.
15. Van Aelst, LNL, Arrigo, M, Placido, R, et al. Acutely decompensated heart failure with preserved and reduced ejection fraction present with comparable haemodynamic congestion. Eur J Heart Fail 20 (2018), 738–747.
16. Harjola, VP, Parissis, J, Brunner-La Rocca, HP, et al. Comprehensive in-hospital monitoring in acute heart failure: applications for clinical practice and future directions for research. A statement from the Acute Heart Failure Committee of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). Eur J Heart Fail 20 (2018), 1081–1099.
17. Ibrahim, NE, Januzzi, JL Jr, The future of biomarker-guided therapy for heart failure after the guiding evidence-based therapy using biomarker intensified treatment in heart failure (GUIDE-IT) study. Curr Heart Fail Rep 15 (2018), 37–43.
18. Felker, G, Anstrom, KJ, Adams, KF, et al. Effect of natriuretic peptide-guided therapy on hospitalization or cardiovascular mortality in high-risk patients with heart failure and reduced ejection fraction: a randomized clinical trial. JAMA 318 (2017), 713–720.
19. Costanzo, MR, Ronco, C, Abraham, WT, et al. Extracorporeal ultrafiltration for fluid overload in heart failure: current status and prospects for further research. J Am Coll Cardiol 69 (2017), 2428–2445.
20. Houston, BA, Kalathiya, RJ, Kim, DA, Zakaria, S, Volume overload in heart failure: an evidence-based review of strategies for treatment and prevention. Mayo Clin Proc 90 (2015), 1247–1261.
21. Colin-Ramirez, E, Ezekowitz, JA, Salt in the diet in patients with heart failure: what to recommend. Curr Opin Cardiol 31 (2016), 196–203.
22. Abraham, WT, Adamson, PB, Bourge, RC, et al. Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial. Lancet 377 (2011), 658–666.
23. Zannad, F, Rossignol, P, Cardiorenal syndrome revisited. Circulation 138 (2018), 929–944.
24. Gerber, Y, Weston, SA, Berardi, C, et al. Contemporary trends in heart failure with reduced and preserved ejection fraction after myocardial infarction: a community study. Am J Epidemiol 178 (2013), 1272–1280.
25. Bonow, RO, Leon, MB, Doshi, D, Moat, N, Management strategies and future challenges for aortic valve disease. Lancet 387 (2016), 1312–1323.
26. Nishimura, RA, Vahanian, A, Eleid, MF, Mack, MJ, Mitral valve disease—current management and future challenges. Lancet 387 (2016), 1324–1334.
27. Rodés-Cabau, J, Taramasso, M, O'Gara, PT, Diagnosis and treatment of tricuspid valve disease: current and future perspectives. Lancet 388 (2016), 2431–2442.
28. Yancy, CW, Jessup, M, Bozkurt, B, et al. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. J Am Coll Cardiol 70 (2017), 776–803.
29. Burnett, H, Earley, A, Voors, AA, et al. Thirty years of evidence on the efficacy of drug treatments for chronic heart failure with reduced ejection fraction: a network meta-analysis. Circ Heart Fail, 10, 2017, e003529.
30. Shen, L, Jhund, PS, Petrie, MC, et al. Declining risk of sudden death in heart failure. N Engl J Med 377 (2017), 41–51.
31. Komajda, M, Cowie, MR, Tavazzi, L, Ponikowski, P, Anker, SD, Filippatos, GS, Physicians' guideline adherence is associated with better prognosis in outpatients with heart failure with reduced ejection fraction: the QUALIFY international registry. Eur J Heart Fail 19 (2017), 1414–1423.
32. Ouwerkerk, W, Voors, AA, Anker, SD, et al. Determinants and clinical outcome of uptitration of ACE-inhibitors and beta-blockers in patients with heart failure: a prospective European study. Eur Heart J 38 (2017), 1883–1890.
33. Epstein, M, Reaven, NL, Funk, SE, McGaughey, KJ, Oestreicher, N, Knispel, J, Evaluation of the treatment gap between clinical guidelines and the utilization of renin-angiotensin-aldosterone system inhibitors. Am J Manag Care 21:suppl 11 (2015), S212–S220.
34. Rossignol, P, Menard, J, Fay, R, Gustafsson, F, Pitt, B, Zannad, F, Eplerenone survival benefits in heart failure patients post-myocardial infarction are independent from its diuretic and potassium-sparing effects. Insights from an EPHESUS (Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study) substudy. J Am Coll Cardiol 58 (2011), 1958–1966.
35. Pitt, B, Anker, SD, Bushinsky, DA, Kitzman, DW, Zannad, F, Huang, IZ, Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial. Eur Heart J 32 (2011), 820–828.
36. Eschalier, R, McMurray, JJ, Swedberg, K, et al. Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure). J Am Coll Cardiol 62 (2013), 1585–1593.
37. Kirchhof, P, Benussi, S, Kotecha, D, et al. 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 37 (2016), 2893–2962.
38. Ferreira, JP, Girerd, N, Alshalash, S, Konstam, MA, Zannad, F, Antithrombotic therapy in heart failure patients with and without atrial fibrillation: update and future challenges. Eur Heart J 37 (2016), 2455–2464.
39. Zannad, F, Anker, SD, Byra, WM, et al. Rivaroxaban in patients with heart failure, sinus rhythm, and coronary disease. N Engl J Med 379 (2018), 1332–1342.
40. Anker, SD, Comin, CJ, Filippatos, G, et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med 361 (2009), 2436–2448.
41. Ponikowski, P, van Veldhuisen, DJ, Comin-Colet, J, et al. Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiencydagger. Eur Heart J 36 (2015), 657–668.
42. Komajda, M, Lam, CS, Heart failure with preserved ejection fraction: a clinical dilemma. Eur Heart J 35 (2014), 1022–1032.
43. Owan, TE, Hodge, DO, Herges, RM, Jacobsen, SJ, Roger, VL, Redfield, MM, Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 355 (2006), 251–259.
44. Bhatia, RS, Tu, JV, Lee, DS, et al. Outcome of heart failure with preserved ejection fraction in a population-based study. N Engl J Med 355 (2006), 260–269.
45. Kitzman, DW, Brubaker, P, Morgan, T, et al. Effect of caloric restriction or aerobic exercise training on peak oxygen consumption and quality of life in obese older patients with heart failure with preserved ejection fraction: a randomized clinical trial. JAMA 315 (2016), 36–46.
46. Dalos, D, Mascherbauer, J, Zotter-Tufaro, C, et al. Functional status, pulmonary artery pressure, and clinical outcomes in heart failure with preserved ejection fraction. J Am Coll Cardiol 68 (2016), 189–199.
47. Kitzman, DW, Shah, SJ, The HFpEF obesity phenotype: the elephant in the room. J Am Coll Cardiol 68 (2016), 200–203.
48. Wolsk, E, Claggett, B, Kober, L, et al. Contribution of cardiac and extra-cardiac disease burden to risk of cardiovascular outcomes varies by ejection fraction in heart failure. Eur J Heart Fail 20 (2018), 504–510.
49. Campbell, RT, McMurray, JJ, Comorbidities and differential diagnosis in heart failure with preserved ejection fraction. Heart Fail Clin 10 (2014), 481–501.
50. Solomon, SD, Anavekar, N, Skali, H, et al. Influence of ejection fraction on cardiovascular outcomes in a broad spectrum of heart failure patients. Circulation 112 (2005), 3738–3744.
51. Shah, KS, Xu, H, Matsouaka, RA, et al. Heart failure with preserved, borderline, and reduced ejection fraction: 5-year outcomes. J Am Coll Cardiol 70 (2017), 2476–2486.
52. Yusuf, S, Pfeffer, MA, Swedberg, K, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 362 (2003), 777–781.
53. Cleland, JG, Tendera, M, Adamus, J, Freemantle, N, Polonski, L, Taylor, J, The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J 27 (2006), 2338–2345.
54. Massie, BM, Carson, PE, McMurray, JJ, et al. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med 359 (2008), 2456–2467.
55. Pitt, B, Pfeffer, MA, Assmann, SF, et al. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med 370 (2014), 1383–1392.
56. Solomon, SD, Rizkala, AR, Gong, J, et al. Angiotensin receptor neprilysin inhibition in heart failure with preserved ejection fraction: rationale and design of the PARAGON-HF trial. JACC Heart Fail 5 (2017), 471–482.
57. Rogers, JK, Pocock, SJ, McMurray, JJ, et al. Analysing recurrent hospitalizations in heart failure: a review of statistical methodology, with application to CHARM-Preserved. Eur J Heart Fail 16 (2014), 33–40.
58. Pfeffer, MA, Claggett, B, Assmann, SF, et al. Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial. Circulation 131 (2015), 34–42.
59. Hoendermis, ES, Liu, LC, Hummel, YM, et al. Effects of sildenafil on invasive haemodynamics and exercise capacity in heart failure patients with preserved ejection fraction and pulmonary hypertension: a randomized controlled trial. Eur Heart J 36 (2015), 2565–2573.
60. Redfield, MM, Chen, HH, Borlaug, BA, et al. Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial. JAMA 309 (2013), 1268–1277.
61. Redfield, MM, Anstrom, KJ, Levine, JA, et al. Isosorbide mononitrate in heart failure with preserved ejection fraction. N Engl J Med 373 (2015), 2314–2324.
62. Pieske, B, Maggioni, AP, Lam, CSP, et al. Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: results of the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED EF (SOCRATES-PRESERVED) study. Eur Heart J 38 (2017), 1119–1127.
63. Solomon, SD, Zile, M, Pieske, B, et al. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet 380 (2012), 1387–1395.
64. Fitchett, D, Butler, J, van de Borne, P, et al. Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME(R) trial. Eur Heart J 39 (2018), 363–370.
65. Radholm, K, Figtree, G, Perkovic, V, et al. Canagliflozin and heart failure in type 2 diabetes mellitus: results from the CANVAS program (Canagliflozin Cardiovascular Assessment Study). Circulation 138 (2018), 458–468.
66. Redfield, MM, Heart failure with preserved ejection fraction. N Engl J Med 375 (2016), 1868–1877.
67. Reddy, YNV, Carter, RE, Obokata, M, Redfield, MM, Borlaug, BA, A simple, evidence-based approach to help guide diagnosis of heart failure with preserved ejection fraction. Circulation, 2018 published online May 23. DOI:10.1161/CIRCULATIONAHA.118.034646 (preprint).
68. Ponikowski, P, Voors, AA, Anker, SD, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 18 (2016), 891–975.
69. Heidenreich, PA, Albert, NM, Allen, LA, et al. Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association. Circ Heart Fail 6 (2013), 606–619.
70. Christ, M, Stork, S, Dorr, M, et al. Heart failure epidemiology 2000–2013: insights from the German Federal Health Monitoring System. Eur J Heart Fail 18 (2016), 1009–1018.
71. Omersa, D, Farkas, J, Erzen, I, Lainscak, M, National trends in heart failure hospitalization rates in Slovenia 2004–2012. Eur J Heart Fail 18 (2016), 1321–1328.
72. Solomon, SD, Dobson, J, Pocock, S, et al. Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure. Circulation 116 (2007), 1482–1487.
73. Kristensen, SL, Jhund, PS, Kober, L, et al. Comparison of outcomes after hospitalization for worsening heart failure, myocardial infarction, and stroke in patients with heart failure and reduced and preserved ejection fraction. Eur J Heart Fail 17 (2015), 169–176.
74. Crespo-Leiro, MG, Anker, SD, Maggioni, AP, et al. European Society of Cardiology Heart Failure Long-Term Registry (ESC-HF-LT): 1-year follow-up outcomes and differences across regions. Eur J Heart Fail 18 (2016), 613–625.
75. Chioncel, O, Mebazaa, A, Harjola, VP, et al. Clinical phenotypes and outcome of patients hospitalized for acute heart failure: the ESC Heart Failure Long-Term Registry. Eur J Heart Fail 19 (2017), 1242–1254.
76. Arrigo, M, Gayat, E, Parenica, J, et al. Precipitating factors and 90-day outcome of acute heart failure: a report from the intercontinental GREAT registry. Eur J Heart Fail 19 (2017), 201–208.
77. Ferrari, R, Bueno, H, Chioncel, O, et al. Acute heart failure: lessons learned, roads ahead. Eur J Heart Fail 20 (2018), 842–850.
78. Harjola, VP, Mullens, W, Banaszewski, M, et al. Organ dysfunction, injury and failure in acute heart failure: from pathophysiology to diagnosis and management. A review on behalf of the Acute Heart Failure Committee of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). Eur J Heart Fail 19 (2017), 821–836.
79. Mebazaa, A, Yilmaz, MB, Levy, P, et al. Recommendations on pre-hospital & early hospital management of acute heart failure: a consensus paper from the Heart Failure Association of the European Society of Cardiology, the European Society of Emergency Medicine and the Society of Academic Emergency Medicine. Eur J Heart Fail 17 (2015), 544–558.
80. Gayat, E, Arrigo, M, Littnerova, S, et al. Heart failure oral therapies at discharge are associated with better outcome in acute heart failure: a propensity-score matched study. Eur J Heart Fail 20 (2018), 345–354.
81. Cheema, B, Ambrosy, AP, Kaplan, RM, et al. Lessons learned in acute heart failure. Eur J Heart Fail 20 (2018), 630–641.
82. Packer, M, Acute heart failure is an event rather than a disease: plea for a radical change in thinking and in therapeutic drug development. JACC Heart Fail 6 (2018), 73–75.
83. Mebazaa, A, Acute heart failure deserves a log-scale boost in research support: call for multidisciplinary and universal actions. JACC Heart Fail 6 (2018), 76–79.
84. Cooper, LB, Hammill, BG, Peterson, ED, et al. Consistency of laboratory monitoring during initiation of mineralocorticoid receptor antagonist therapy in patients with heart failure. JAMA 314 (2015), 1973–1975.
85. Nilsson, E, De Deco, P, Trevisan, M, et al. A real-world cohort study on the quality of potassium and creatinine monitoring during initiation of mineralocorticoid receptor antagonists in patients with heart failure. Eur Heart J Qual Care Clin Outcomes, 2018 published online May 2. DOI:10.1093/ehjqcco/qcy019 (preprint).
86. McAlister, FA, Stewart, S, Ferrua, S, McMurray, JJ, Multidisciplinary strategies for the management of heart failure patients at high risk for admission: a systematic review of randomized trials. J Am Coll Cardiol 44 (2004), 810–819.
87. Alla, F, Agrinier, N, Lavielle, M, et al. Impact of the interruption of a large heart failure regional disease management programme on hospital admission rates: a population-based study. Eur J Heart Fail 20 (2018), 1066–1068.
88. Laborde-Casterot, H, Agrinier, N, Zannad, F, et al. Effectiveness of a multidisciplinary heart failure disease management programme on 1-year mortality: prospective cohort study. Medicine (Baltimore), 95, 2016, e4399.
89. Agrinier, N, Altieri, C, Alla, F, et al. Effectiveness of a multidimensional home nurse led heart failure disease management program—a French nationwide time-series comparison. Int J Cardiol 168 (2013), 3652–3658.
90. Hernandez, AF, Greiner, MA, Fonarow, GC, et al. Relationship between early physician follow-up and 30-day readmission among Medicare beneficiaries hospitalized for heart failure. JAMA 303 (2010), 1716–1722.
91. Sarwar, CM, Papadimitriou, L, Pitt, B, et al. Hyperkalemia in heart failure. J Am Coll Cardiol 68 (2016), 1575–1589.
92. Anker, SD, Koehler, F, Abraham, WT, Telemedicine and remote management of patients with heart failure. Lancet 378 (2011), 731–739.
93. Yun, JE, Park, JE, Park, HY, Lee, HY, Park, DA, Comparative effectiveness of telemonitoring versus usual care for heart failure: a systematic review and meta-analysis. J Card Fail 24 (2018), 19–28.
94. Fraiche, AM, Eapen, ZJ, McClellan, MB, Moving beyond the walls of the clinic: opportunities and challenges to the future of telehealth in heart failure. JACC Heart Fail 5 (2017), 297–304.
95. Boehmer, JP, Hariharan, R, Devecchi, FG, et al. A multisensor algorithm predicts heart failure events in patients with implanted devices: results from the MultiSENSE study. JACC Heart Fail 5 (2017), 216–225.
96. Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 362 (2003), 1527–1535.
97. Thomopoulos, C, Parati, G, Zanchetti, A, Effects of blood pressure-lowering treatment. 6. Prevention of heart failure and new-onset heart failure—meta-analyses of randomized trials. J Hypertens 34 (2016), 373–384.
98. Zinman, B, Wanner, C, Lachin, JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373 (2015), 2117–2128.
99. Butler, J, Hamo, CE, Filippatos, G, et al. The potential role and rationale for treatment of heart failure with sodium-glucose co-transporter 2 inhibitors. Eur J Heart Fail 19 (2017), 1390–1400.
100. Preiss, D, Campbell, RT, Murray, HM, et al. The effect of statin therapy on heart failure events: a collaborative meta-analysis of unpublished data from major randomized trials. Eur Heart J 36 (2015), 1536–1546.
101. Djousse, L, Driver, JA, Gaziano, JM, Relation between modifiable lifestyle factors and lifetime risk of heart failure. JAMA 302 (2009), 394–400.
102. Florido, R, Kwak, L, Lazo, M, et al. Six-year changes in physical activity and the risk of incident heart failure: ARIC study. Circulation 137 (2018), 2142–2151.
103. Dagenais, GR, Pogue, J, Fox, K, Simoons, ML, Yusuf, S, Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials. Lancet 368 (2006), 581–588.
104. Ferreira, JP, Machu, JL, Girerd, N, et al. Rationale of the FIBROTARGETS study designed to identify novel biomarkers of myocardial fibrosis. ESC Heart Fail 5 (2018), 139–148.